Administration of Eculizumab, a C5 Inhibitor, for the Treatment of Shiga-Toxin-Producing Escherichia coli Infection: A Case Report
作者: Takahiro Yukawa Takuto Ishida Toshinobu Yamagishi Kazuhiro Sugiyama Yuichi Hamabe
刊名: American Journal of Clinical and Experimental Medicine, 2018, Vol.6 (1)
来源数据库: Science Publishing Group
DOI: 10.11648/j.ajcem.20180601.15
关键词: Hemolytic-Uremic SyndromeShiga-Toxin-Producing Escherichia coli InfectionAcute EncephalopathyEculizumab
原始语种摘要: Hemolytic-uremic syndrome (HUS), which is characterized by microvascular hemolytic anemia, consumption thrombocytopenia, and acute renal failure, is a complication of the Shiga-toxin-producing Escherichia coli (STEC) infection. We describe the case of a patient who, despite undergoing plasma exchange and renal replacement therapy for STEC-induced HUS, experienced poor improvement in platelet count, serum creatinine level, and serum lactate dehydrogenase level. The patient developed acute encephalopathy but recovered without permanent organ damage after eculizumab therapy. For severe HUS cases involving the central nervous system, early administration of eculizumab, which inhibits the abnormal activation of the complement activation pathway, may be effective.
全文获取路径: PDF下载  SciencePG  (合作)
分享到:

×
关键词翻译
关键词翻译
  • 轨道 改良
  • Escherichia 埃希氏菌属
  • encephalopathy 脑病
  • uremic 尿毒症的
  • renal 肾的
  • activation 活化
  • despite 不管
  • administration 管理
  • improvement 改良
  • pathway 改良
  • dehydrogenase 脱氢酶